Background.A review of the efficacy of antidepressantdrug treatment in patients with obsessiveâ€"compulsive disorder(OCD), using a meta-analyticapproach. Method. Randomiseddouble-blindclinicaltrials of antidepressantdrugs, carriedout among patients with OCD and publishedin peer-reviewedjournalsbetween 1975 and May 1994, were selectedtogether with three studiescurrentlyin press.Forty-seventrials were located by searchingthe Medlineand ExcerptaMedica â€"¿ Psychiatrydata bases,scanningpsychiatric and psychopharmacological journals,consultingrecentpublishedreviewsand bibliographies, contactingpharmaceutical companiesandthroughcross-references. Hedges'g was computed in pooleddata at the conclusionof treatment underdouble-blindconditionsor at the latest reportedpointof time duringthistreatmentperiod.Foreachtrial, effect sizeswere computed for allavailableoutcomemeasuresof the followingdependentvariables: obsessiveâ€"compulsive symptomsconsideredtogether;obsessions; compulsions; depression; anxiety;globalclinical improvement;psychosocialadjustment;and physicalsymptoms. Results. Clomipramine was superior to placeboinreducing bothobsessive-compulsive symptoms consideredtogether(g= 1.31; 95% Cl= 1.l5to 1.47) as well asobsessions(g=0.89, 95% Cl = 0.36 to 1.42) andcompulsionstg= 0.79; 95% Cl= 0.34 to 1.24) takenseparately.Also, selectiveserotoninre-uptakeinhibitors(SSRIs)as a classwere superiorto placebo,weighted meang beingrespectively0.47 (95% Cl= 0.33 to 0.61), 0.54 (95% Cl = 0.34 to 0.74) and 0.52 (95% Cl = 0.34 to 0.70) for obsessiveâ€"compulsive symptomsconsideredtogether,and obsessions andcompulsions takenseparately. Althoughon Y-BOCSthe increase in improvement rate over placebo was 61.3%, 28.5%, 28.2% and 21.6% for clomipramine,fluoxetine, fluvoxamine, and sertraline respectively, the trials testing clomipramine against fluoxetine and fluvoxamine showed similar therapeutic efficacy between these drugs. Finally, both clomipramine andfluvoxamine provedsuperior to antidepressant drugswith noselective serotonergic properties. Conclusion. Antidepressant drugsareeffectiveinthe short-termtreatmentof patientssuffering from OCD; although the increase in improvement rate over placebo was greater for clomipraminethan for SSRIs,directcomparisonbetween these drugsshowedthat they had similartherapeuticefficacyonobsessive-compulsive symptoms; clomipramine andfluvoxamine had greater therapeutic efficacy than antidepressantdrugs with no selective serotonergic properties;concomitanthigh levelsof depressionat the outset did not seem necessaryfor clomipramineand for SSRIsto improveobsessiveâ€"compulsive symptoms.
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point when inferences are drawn from heterogeneous but related studies; furthermore, at that time no trials were available on novel SSRIs, which are now considered to be effective in patients with OCD. More recently, Jenike et a! (1990b,c) applied meta analytic techniques to four controlled or open trials testing serotonergic drugs in patients with OCD, but only a single effect size was available per medication. As a consequence, conclusions based on these meta analyses remain guarded.
The aim of this paper is to review the efficacy of antidepressant drug treatment in patients with OCD, using a meta-analytic approach and restrictive criteria for selection of trials to be pooled. Addressing this topic is important for at least four reasons. First, research carried out over the past two decades has challenged the traditional belief that OCD is a rare and treatment-resistant illness. Data collected in the general population during the National Epidemiologic Catchment Area project revealed a one-month prevalence of 1.3% and a lifetime prevalence of 2.5%, with OCD ranking fourth in prevalence after substance abuse, affective disorders and phobias (Robins et a!, 1984; Regier et a!, 1993) . Second, since OCD is often severe and interferes significantly with occupational functioning and social activities, effective treatments are particularly warranted. Recent advances in both the behavioural and psychopharmacological management of OCD have shown that between 60Â°lo and 80% of patients can benefit from treatment (Perse, 1988 ; Goodman et a!, 1992).
Third, increased knowledge of the disorder and its treatment hasfostered greater public awareness. It has been featured in a best-selling book (Rapoport, 1989) and has been a topic in major newspapers and magazines, and on television and radio talk-shows. Moreover, between 1985 and 1986 the Obsessive Compulsive Disorder Foundation was set up in the United States and since then has been acting as a national referral network and information clearing house across that country (Ricciardi, 1993) ; similar networks may be operating in other countries as well. Clearly, these efforts might result in an increasing number of patients seeking treatment for their disorder.
Finally, although behaviour therapy is considered bysomeasthetreatment ofchoice forOCD (because it has been reported to be more effective than pharmacological interventions and to provide long term improvement with low relapse rate), in reality few patients actually undergo this treatment, either as a result of refusing to participate, high cost, and/or a lack of qualified behavioural therapists (Leonard et a!, 1993) . Also, severe depression may interefere with behaviour therapy (Foa& Emmelkamp, 1983) , and about two-thirds of patients with OCD have a lifetime history of major depression and one third satisfy criteria for major depression at the time of first evaluation (Rasmussen & Eisen, 1992). Thus, psychotropic drugs often represent the main treat ment which is readily available to the majority of patients suffering from OCD.
Selection of studies
Method
Studies on antidepressant drug treatment of patients with OCD published in peer-reviewed journals between 1975 and May 1994 were selected together with three studies in press, provided by pharma ceutical companies (Freeman et a!; Greist et a!; Rasmussen et aD. Studies were located by searching the Medline and Excerpta Medica â€"¿ Psychiatry data bases, using the keyword â€˜¿ obsessiveâ€"compulsive disorder' matched with any of the following in the title orabstract: â€˜¿ clinical trial', â€˜¿ comparative study', â€˜¿ prospective study', â€˜¿ evaluation study', â€˜¿ double-blind method', and â€˜¿ random allocation'. As abstracts were available on Medline from 1975, that was considered the best year to start the search. In addition, literature was supplemented by scanning psychiatric and psychopharmacological journals (full list avail able from authors), by consulting recent published reviews and bibliographies, by contacting pharma ceutical companies (see Acknowledgements) and by checking references in the papers so located.
In orderto compareand integrate methodolo gically similar studies, clinical trials were included in analyses provided that randomisation was used in treatment assignment and alternative drug treatments were administered under double-blind conditions for atleast four weeks. Trials ontreatment augmentation in patients refractory to standard treatments as well asthose carried outamong patients withOCD and comorbid Tourette's syndrome were not included.
A total of 53 articles meeting the selection criteria were found. Of these, 13 were not included in the analyses: one selected patients with either phobic or obsessiveâ€"compulsive neurosis (Amin et a!, 1977); one selected patients suffering from depression with obsessive-compulsive and phobic traits (Karabanow, 1977) ; one selected patients with phobicâ€"obsessive psychoneurosis, but â€oe¿ the diagnostic criteria were not strictly enforcedâ€•(Cassano eta!, 1981); one selected patients with compulsive neurosis or polymorphic neurosis with compulsive neurotic symptoms pre dominating (Jaskari, 1980); two selected patients with anxiety disorders, including OCD, agoraphobia with or without panic attacks and generalised anxiety disorder (Den Boer et a!, 1987; Khan et a!, 1987) ; one did not allow proper comparison between clomipramine treatment and placebo treatment, as placebo was given for two weeks only, either on the fourth or sixth week during the four-month clomi pramine treatment (Yaryura-Tobias eta!, 1976) ; four (DeVeaugh-Geiss et a!, 1989; Greist et a!, 1990; Mallya eta!, 1992; Hoehn-Saric eta!, 1993) reported on subsamples of patients recruited during two large scale multicentre trials (Clomipramine Collaborative Study Group, 1991; Rasmussen et a!, in press); one (Cottreaux et a!, 1993) Five articles (Rapoport eta!, 1980; Mavissakalian & Michelson, 1983; Insel et a!, 1985; Marks et a!, 1988; Saiz Ruiz et a!, 1992) contained insufficient data to compute pre-post-test effect sizes according to different types of treatment. Thus, the first authors were contacted by express mail and original data were requested. Original data were sent promptly by one of them (Marks), another (Rapoport) stated that data were no longer available, while three gave no reply over a three-month period. As a consequence, only the study by Marks et a! (1988) was included in analyses. As to the trials that were excluded, Rapoport et a! (1980) tested clomipramine, desipramine and placebo in nine adolescents; Mavissakalian & Michelson (1983) A large-scale (355 patients) multicentre trial of fluoxetine carried out in the USA and published so far only in abstract form (Tollefson eta!, 1993) could not be included in the overall analyses, as efforts to get original data from Eli Lilly failed. However, since mean scores on the Yaleâ€"Brown Obsessive Compulsive Scale (Yâ€"BOCS) at the outset and at the end of trial were published by Wood et a! (1993) , these data were included in the analyses limited to Y-BOCS.
Of the 36 articles which were retained, one reported results from two distinct controlled clinical trials, two tested two different antidepressant drugs against placebo, and three reported on the effect of three fixed daily doses of fluoxetine or sertraline against placebo; thus a comparison was available between two different types of treatment in 47 trials. The trials included in the analyses, each with its main characteristics and corresponding effect sizes, are shown in the Appendix.
Although all trials satisfied two basic standards for scientific precision (i.e. the randomisation and blinding of treatment), in 28 (59.6%) outcome was assessed among subjects completing the trial (or a sufficient part of it) and not among all those initially allocated to treatment in spite of some patients not actually receiving it (i.e. â€˜¿ intention-to-treat' analysis). As a consequence, the principle of equal opportunity to receive experimental and control treatment was not preserved and this might be a possible bias in the results. In the Appendix both the number of patients who were randomised to treatment and the number of patients included in the analyses are reported.
Published clinical trials may be biased in favour of significant results, since trials failing to show any treatment difference may be less likely to be published â€"¿ investigators may not submit them for publication and editors may reject them. Thus a meta-analysisbased only on publishedtrialsmay lead to biased conclusions. In order to overcome this, it has been suggested that a meta-analysis should include all relevant data, whether published in original articles, abstracts or letters or not published at all (Collins eta!, 1987; Yusuf, 1987) . This has two major drawbacks. First, unpublished data would be retrieved through informal contacts (e.g. corres pondence, meetings, lectures), since a register of planned and in-progress clinical trials is not yet available in the field of psychiatry as it is in other research areas, such as cancer (Simes, 1987; Easterbrook, 1992) .Variability and incompleteness of inclusion would be inevitable. Second, the quality of the data collected through informal contacts cannot be assured:
it is important to blind the randomisation, withdrawal and analysis processes in the original randomised control trials, it is equally important to control bias in obtaining these data for a meta-analysis, and this is not possible when the formal publication processhas not been followed.â€ • (Chalmerseta!, 1987) Since double-blind randomised prospective trials (the only ones included in the present meta-analysis) are more likely to be published irrespective of their results, in light of the effort going into them (Begg, 1985) , and since peer review is an important means of ensuring quality, the present analyses were based only on published or in press data.
Psychotherapy
Three of the 33 trials included psychotherapy in the study design. These were: (a) Marks et a! (1980) , in which exposure and relaxation were randomly DRUG TREATMENT IN OBSESSIVE-COMPULSIVEDISORDER allocated to patients receiving either clomipramine or placebo for six weeks. In the present analyses, effect sizes were computed based on comparison between clomipramine and placebo at week 36; (b) Marks eta! (1988) , in which clomipramine treatment was compared to placebo treatment and three types of exposure. In the present analyses, effect sizes were computed based on comparison between clomipramine and placebo under similar exposure conditions at week 23; (c) Cottreaux eta! (1990), in which patients were offered fluvoxamine or placebo in combination with exposure or anti-exposure. In the present analyses, effect sizes were computed based on comparison between fluvoxamine and placebo under similar exposure conditions at week 24.
Age
All but four studies (Flament et a!, 1985; Leonard eta!, 1988 Leonard eta!, , 1989 DeVaugh-Geiss eta!, 1992) 
Calculation of effect size
Various effect size estimators have been proposed and discussed in the scientific literature (Rosenthal, 1984; Demets, 1987) . Odds ratios based on Mantel Haenszel's test (Mantel & Haenszel, 1959) (Armitage & Berry, 1987) . Findings only reported as statistically significant were treated as significant at the conventional 0.05 level (two-tailed F). Similarly, a conservative approach was used when P values were given imprecisely as <0.05 or <0.01, since they were assumed to be significant at the 0.05 or 0.01 level, respectively. Finally, in order to avoid possible bias arising from studies reporting only sig nificant results, findings simply defined as non significant or with undefined P's were treated as having a P of 0.50 and an effect size equal to zero.
Of the 47 selected trials, 44 allowed for precise estimates of all or part of their effect sizes; one expressed results only in terms of improvement/non improvement; one reported only round levels of significance; and one reported both ratings of improvement and round levels of significance. Overall, 2% effect sizes were computed: 264 (89.2Â°lo) were based on exact statistics; 19 (6.4Â°lo) on round levels of significance; and 13 (4.4%) on ratings of improvement. Although imprecise estimates based on round levels of significance or ratings of improvement introduced a bias in the analyses, this is likely to be small and would not distort the results to a significant degree in light of the limited number of such estimates.
Dependent variables
For each trial, effect sizes were computed for all available outcome measures of the following dependent variables: obsessive-compulsive symptoms considered together; obsessions; compulsions; de pression; anxiety; global clinical improvement; psychosocial adjustment; and physical symptoms. If more than one measure was available for a particular dependent variable, it was included, providing that it gave no duplicated information. Effect sizes were computed for each measure at the conclusion of treatment under double-blind conditions or at the latest reported point of time during this treatment period.
computed. Demets (1987) suggested that the fixed effects model and the conditional inference on the trials actually done seem most suitable:
â€oe¿ While somemeasureof betweenstudyvariabilitymay be useful, one can easilyget into an awkwardsituation if the random effects approach is taken formally. Two studies might differ substantially in size of effect but each be significant on their own. Yet, combined with a betweenstudycomponent of variation, theresultsmay not allowa claimof a statisticallysignificantdifference. One can also questionwhetherthere reallyis a universe of trials.â€• In our analyses, we adopted a fixed effects model. Within each treatment class and for the dependent variables listed above, a weighted mean g was computed by combining the gs of independent trials, each weighted by the reciprocal of its esimated variance. @ test for heterogeneity of the set of gs was also applied (Rosenthal & Rubin, 1982).
Results
Placebo-controlled trials (n = 26)
Non-independent data
Several effect size estimates that are not statistically independent may be generated by the same subjects within each trial, either because they come from different outcome measures or from the same measure collected at different points of time during the study period. Since the methods of combining probability levels require independent research results, non-independence of data can be a major drawback of meta-analytic procedures. Following the suggestion by Christensen et a! (1987), we tried to overcome this problem by considering each trial (rather than each effect size) as the unit of analysis.
Thus, with trials reporting more than one effect size for a particular dependent variable, a mean effect size for that variable was computed. Although two studies (Thoren eta!, 1980; Hewlett eta!, 1992 )tested more than one treatmentcondition against each other and consequently might have given rise to partially dependent measures, each comparison between two different types of treatmentwas assigned to different treatment classes (see below) and thus was considered as independent in the analyses.
Treatment classification
Aggregation of trials was based on the classification of the main neurotransmitter re-uptake blockade exerted by the drugs which were tested, and the following classes were devised: Clomipramine was considered separately as it is the drug most studied and tested in OCD.
Much controversy still surrounds the assessment of an overall treatment effect based on several independent trials and two statistical models have been proposed. Under the fixed effects model the outcome on a particular treatment is assumed to be the same from one trial to the next and only a within trial variability is considered, as variations in treatment effect across trials are attributed to sampling differences in patient populations. Alter natively, the random effects model implies that the pooled trials are a random sample of some universe of trials, each estimating a different treatmenteffect; thus both a within and a between trial variability are 4 Eleven trials (733 patients) compared the relative efficacy of clomipramine against placebo; 13 trials (1076patients) tested SSRIs against placebo (five using fluvoxamine, three fluoxetine and five sertraline); and two trials tested other tricycic antidepressants (imipramine and nortriptyine) in a sample of 53 patients. Since six trials of SSRIs were provided by two dose-fmding investigations (Montgomery eta!, 1993; Greist eta!, in press), testing respectively three fixed doses of fluoxetine (20 mg, 40mg, 60mg) and three fixed doses of sertraline (50 mg, 100 mg, 200 mg) against placebo, in the analyses we chose to combine only the two trials showing greater efficacy of drugs over placebo (i.e. those using 60mg of fluoxetine and 200mg of sertraline, respectively).
Obsessiveâ€"compulsivesymptoms considered together,obsessions and compulsions
For obsessiveâ€"compulsivesymptoms considered together, and for obsessions and compulsions taken separately, Table 1 shows the weighted mean effect sizes (and corresponding 95% confidence intervals (CI)) computed from the trials testing clomipramine and SSRIs against placebo.
Clomipramine was superior to placebo in reducing both obsessiveâ€"compulsive symptoms considered together, and obsessions and compulsions taken separately; however, for each of the three dependent variables @ test for heterogeneity of gs showed large variation around the mean. For each of the three dependent variables, a linear regression equation of the log5 transformation of the effect size was fit on the following independent variables: mean age of the sample (in years); mean duration of obsessive compulsive symptoms at the outset of the trial (in years); presence (1) or absence (0) of depression at the outset of the trial; setting (out-patients, in patients, or both); sample size; percentage of males; maximum clomipramine dose; length of trial (in weeks). The following model explained 95Â°lo of the variation in effect sizes of obsessiveâ€"compulsive symptoms considered together:
log5 (OCD) = 1.52â€" 0.97 (depression at the outset) â€"¿ 0.33 (mean age).
For obsessions and compulsions rated separately, none of the selected independent variables was entered in the model. Also, SSRIs as a class were superior to placebo, although less effective than clomipramine on obsessive-compulsive symptoms considered together; x2 test for heterogeneity of gs gave no significant results, pointing to a close correspondence between the effect sizes computed from trials testing different SSRIs. Finally, for other tricycic antidepressants only a single effect size was available per dependent variable: a g of 0.50 (95% CI: â€"¿ 0.50 to 1.50) was obtained for obsessiveâ€"compulsive symptoms considered together; for obsessions and compulsions taken separately g was 0.60(95% CI: â€"¿ 0.40 to 1.60) and 0.12 (95% CI: 0.53 to 0.77), respectively.
Depression, anxiety, g!oba! dinica! improvement and psychosocia! adjustment
For depression, anxiety, global clinical improvement and psychosocial adjustment, Table 2 sets out the weighted mean effect sizes (and corresponding 95% CI) computed from the trials testing clomipramine and SSRIs against placebo.
Clomipramine was superior to placebo according to each dependent variable; however, effect sizes provided by independent trials were significantly heterogeneous for global clinical improvement. As expected, the therapeutic effect of clomipramine was accompanied by physical side-effects: the only trial comparing physical symptoms, induced by clomi pramine and placebo respectively, gave a g of â€"¿ 1.13 (95% CI = â€"¿ 1.82 to 0.44) (Flament et a!, 1985) . SSRIs as a class were superior to placebo and similar in efficacy to clomipramine; however, for global clinical improvement @2 test for heterogeneity of gs showed significant variation around the mean. Lastly, for other tricyclic antidepressants a single effect size was available only for depression (g = 0.99; 95% CI: 0.30 to 1.68) and psychosocial adjustment (g=0.30; 95% CI: â€"¿ 0.68 to 1.28).
Selective effect of clomipramine on obsessive compulsive symptoms A selective effect of clomipramine on obsessive compulsive symptoms, which might be independent from its antidepressant properties, was investigated by testing the relative efficacy of clomipramine treatment v. placebo treatment according to patients' levels of depression at the outset of the trial. For this purpose, the trials excluding patients with a substantial degree of depression at the outset â€"¿ i.e. no primary affective disorder and/or a baseline score lower than 17 on the Hamilton Depression Rating Scale (HDRS) (Hamilton, 1960) -were compared to those trials in which patients with OCD might have concomitant depression.
For obsessiveâ€"compulsivesymptoms considered together clomipramine was superior to placebo in both sets of trials (Table 3) (Table 4) , even though the latter findings were based on single effect sizes computed from small samples of patients. x2 test for heterogeneity of gs (when applicable) showed significant differences between effect sizes computed from independent trials for obsessiveâ€"compulsive symptoms considered together, depression and anxiety. 
Othercompounds
Pato et a! (1991) compared clomipramine with buspirone in 18 patients with OCD and found similar efficacy of the two drugs on obsessiveâ€"compulsive symptoms considered together (S = 0.13; 95% CI = â€"¿ 0.79 to 1.05) and depression (S = 0.11; 95Â°/o CI = â€"¿ 0.81 to 1.03), with clomipramine determining greater global clinical improvement (S = 0.56; 95Â°/a CI= â€"¿ 0.38 to 1.50). Hewlett et a! (1992) reported that clomipramine and clonazepam were both more effective than diphenhydramine (a drug with antihistaminic and anticholinergic effects, but with no theoretical or empirical efficacy in patients with OCD) in reducing obsessiveâ€"compulsive symptoms (S = 1.22; 95% CI = 0.61 to 1.83 for clomipramine and g = 0.68; 95Â°/oCI = 0.07 to 1.29); on the other hand, clomipramine was only slightly superior to clonazepam (S=0.52; 95Â°lo CI= â€"¿ 0.09 to 1.13).
Prasad (1984) tested zimeidine against imipramine in six patients with OCD. Zimelidine was more effective than imipramine on obsessive compulsive symptoms (S= 3.46; 95Â°/a CI = 0.59 to 6.34), but not on depression (S = â€"¿ 0.80; 95Â°/o CI= â€"¿ 2.49 to 0.89).
Finally, Pigott et a! (1992) found that trazodone was no better than placebo in reducing obsessive compulsive symptoms (S = 0.23; 95Â°/o CI = â€"¿ 0.88 to 1.12), even though the study was terminated prematurely because of â€oe¿ lack of efficacy in terms of clinically evident anti-obsessive effects and attrition due to dropouts (19Â°/o of enrolled patients)â€•.
Differential drug effects according to instruments used
In order to control for variation between trials of clomipramine and SSRIs which might stem from the use of different instruments, analyses were repeated including only those trials in which obsessive compulsive symptoms were rated according to either one (or both) of two widely used OCD measures, i.e. the Yâ€"BOCS(Goodman et a!, 1989b,c) and the National Institute of Mental Health Obsessive Compulsive Rating Scale (NIMHâ€"OC) (Murphy et a!, 1982) . Furthermore, therapeutic efficacy was investigated by single drugs rather than combining similar drugs in the same treatment class.
TableS sets out the weighted mean effect sizes (and corresponding 95Â°/o CIs) computed from the trials testing clomipramine and SSRIs against placebo. In relation to Y-BOCS and NIMH-OC, clomipramine showed greater weighted mean effect sizes than SSRIs, even though there was significant variation around the mean; on the other hand, the therapeutic efficacy of fluvoxamine, fluoxetine and sertraline was similar.
NIMH-OCTrials
Since effect sizes computed from independent trials might be influenced by differences in the placebo response between trials, for clomipramine, fluvoxamine and sertraline a linear regression equation of the log transformation of the effect size was fitted on the change of Yâ€"BOCSscore in the placebo group, with each trial being weighted by its estimated variance. For each of the three drug effect sizes were then predicted according to the placebo response found in the fluoxetine study. Clomipramine retained its superiority over SSRIs (S = 1.05); for fluvoxamine and sertraline, g was 0.37 and 0.50, respectively.
Discussion
Although meta-analysis is a long-established and powerful statistical approach to the integration of research findings, three major issues constrain the interpretation of meta-analytic studies (Strube & Hartmann, 1983) . First, it is argued that mets analysis averages over studies differing in their methodology and data quality and this may affect the global picture that is derived. We tried to overcome this possible limitation by including only double-blind randomised clinical trials of anti depressant drugs, carried out among patients suffering from a well-defined disorder (i.e. OCD); testing interaction between sampling and methodological features and effect sizes; and repeating the analyses within treatment classes after blocking on subject characteristics (i.e. level ofdepression attheoutset) and instruments used.
A second criticism refers to problems of in dependence, as several effect size estimates that are not statistically independent may be generated by the same subjects within each study. We attempted to reduce such bias by computing an effect size for every outcome measure that conveyed non-redundant information; considering only the latest reported assessment during the treatment period; and com putinga mean effect size, when multiple effect size estimates were provided for the same dependent variable. In this way, each trial became a separate unit of observation and contributed a single effect size to the final overall analyses.
A final constraint, which applies to traditional literature reviews as well, is publication and selection bias. In the absence of a generally acceptable empiricalsolutionto this issue,we used two approaches to dealing with it. First, two databases wereidentified throughthis integrated approach.In addition, we applied statistical techniques to estimate the extent of publication bias (Rosenthal, 1979 (Rosenthal, , 1984 ). Rosenthal's method involves calculating the number of negative studies that need to be available in pharmaceutical company and other files before the results of a meta-analysis would be negated. Using this technique, we estimated that there would need to be 4820 studies averaging null results (i.e. about 500 times as many as the studies actually done) before the superiority of clomipramine over placebo couldbe regarded as invalid. Similarly, 338 such DRUG TREATMENT IN OBSESSIVE-COMPULSIVEDISORDER negative studies (i.e. about 50 times as many as the studies actually done) would be needed to reject the superiority of clomipramine over other anti depressant drugs with no selective serotonergic properties, and 964 studies (i.e. about 120 times as many as the studies actually done) to dismiss the greater therapeutic efficacy of SSRIs as a class, compared to placebo. Indeed, it is highly unlikely that so many studies were carried out and their results remained unpublished.
Therapeutic efficacy of antidepressant drugs
Compared to placebo, treatment with either clomi pramine, SSRIs (fluoxetine, fluvoxamine or sertraline) or other tricyclic antidepressants (nortryptiline or imipramine) was of greater benefit in terms of obsessiveâ€"compulsive symptoms, and associated depression and anxiety. As might be expected, this drug effect was associated with improved global clinical outcome and psychosocial adjustment, when such measures were provided. Overall, obsessive-compulsive symptoms improved more using clomipramine than using SSRIs or other tricyclic antidepressants. According to the binomial effect size display suggested by Rosenthal (1984) , the increase in improvement rate over placebo was 48.5Â°/a for clomipramine, 28.6Â°/a for SSRIs as a class, and 23.1Â°/o for nortriptyline.
Comparison with placebo in relation to Yâ€"BOCS showed that clomipramine was superior to SSRIs, the increase in improvement rate over placebo being 61.3Â°/a, 28.SÂ°/a, 28.2Â°/a and 21.6% for clomipramine, fluoxetine, fluvoxamine, and sertraline respectively. Similarly, when meta-analytic techniques were applied to four controlled or open trials testing clomipramine, fluoxetine, fluvoxamine and sertraline against placebo in patients with OCD at the Massachusetts General Hospital, clomipramine showed a greater therapeutic effect than SSRIs (Jenike et a!, 1990a,c). Finally, paroxetine has been tested against placebo in one double-blind randomised clinical trial involving 348 patients, but initial results have only been presented in poster form (Wheadon et a!, 1993) and were not included in our analyses. However, available data suggest that paroxetine is effective in patients with OCD, since a statistically significant improvement over placebo was obtained using 40 mg and 60 mg of paroxetine daily over a 12-week period.
Although results provided by placebo-controlled trials may suggest differences in therapeutic efficacy between drugs, inferences should be made with caution, as differences between effect sizes might be due also to differences in sample size (although partially corrected by the weighting procedure) as well as in patient characteristics, or both. A direct means by which differential treatment effects can be investigated is provided by trials testing two drugs against each other. In this respect, both clomipramine and fluvoxamine proved superior to antidepressant drugs with no selective serotonergic properties: compared to desipramine, the increase in improve ment rate produced by clomipramine and fluvoxamine was 47.4Â°lo and 57.7Â°/o, respectively. On the other hand, similar therapeutic efficacy was found when clomipramine was tested against fluoxetine and fluvoxamine, although more physical side-effects were reported by patients receiving clomipramine.
Effectiveness of treatment
This review addressed the issue of efficacy of anti depressant drugs in patients with OCD, which is conceptually to be distinguished from effectiveness.
Efficacy refers to the therapeutic potential of a treatment and is usually assessed by double-blind randomised clinical trials. Effectiveness reflects actual results obtained in standard clinical practice and depends upon efficacy together with a set of other variables, such as the diagnostic accuracy in the field, the compliance to treatment and the utilisation of treatment by patients who can benefit from it (Guscott & Taylor, 1994) .
Long-term follow-up studies of patients with OCD (Markset a !,1980 ,1988 Mawson et a!,1982; Cottreaux eta!, 1990 Cottreaux eta!, , 1993 suggest that the effective ness of antidepressant drugs may be much lower than their efficacy, since patients initially responding to drugs retain only part of their improvement in the long term and often relapse on stopping medications. Leonard et a! (1993) evaluated 54 children and adolescents two to seven years after initial 5-week double-blind clomipramine treatment. Interim evaluations showed that many patients had a waxing and waning course of ifiness, and on follow-up 43Â°/o still met DSMâ€"IIIâ€"R(American Psychiatric Association, 1987) diagnostic criteria for OCD and only 6Â°lo could be considered in true remission, in spite of 70Â°/o taking psychoactive medication. Further more, a delay of up to ten years has been reported for patients with OCD to come to medical attention, with many patients never disclosing their disorder to a doctor. Indeed, the data collected during the Epidemiologic Catchment Area project revealed that only 34Â°/o of the subjects with a lifetime diagnosis of OCD and 20% of those with active one-year disorder ever mentioned their symptoms to a doctor (Robins & Regier, 1991) . It follows that efforts should be directed at narrowing the gap between efficacy and effectiveness of antidepressant treatment, if the alleged benefits are to be extended.
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Efficiency of treatment
A final issue to be considered isthe economic evaluation ofdifferent therapeutic options inorder to determine the efficiency of each treatment (Eccleston, 1993) . To our knowledge, no such evaluation has been done for OCD. Although it is largely accepted that alternative drugs available to patients with OCD are mainly clomipramine and SSRIs, relatively little is known about the preferential response of some patients to one drug, while not or partially responding to others. The same is true for the potential of augmentation strategies and of combined interventions, such as drugs and behaviour therapy. Thus, large-scale controlled comparative studies are required in which competing therapeutic options are no longer evaluated only in terms of morbidity, but in a way that includes economic costs and benefits along with quality-of-life measures.
Levels of depression at the outset, and improvement of obsessiveâ€"compulsivesymptoms In a review of studies carried out among patients with phobic or obsessiveâ€"compulsivedisorder, Marks (1982) found that one predictor of drug effect seemed to be the level of depression at the outset, drug effect generally being absent where this was low. Further more, two studies compared patients suffering from OCD with the highest and lowest levels of depression at the start and found that the overall effect of clomipramine could be ascribed mainly to those patients with the highest levels of depression (Marks et a!, 1980; Thoren et a!, 1980) . Subsequent studies challenged these results, suggesting that clomipramine may have a specific anti-obsessional effect and not merely an anti depressant action in patients who frequently develop secondary depression during the course of OCD (Insel et a!, 1983; Mavissakalian et a!, 1985) . Our findings support this view and show that high levels of depression are not required in patients with OCD forclomipramine to reduce obsessiveâ€"compulsive symptoms. In fact, greater weighted mean effect sizes forobsessiveâ€"compulsive symptomswereprovided bytrials testing clomipramine against placebo among patients with low levels of depression at the outset. For SSRIs conclusions are somewhat limited because ofthelowernumberoftrials conducted sofar, but these drugs also proved superior toplacebo intrials conducted among non-depressed patients withOCD.
Inanycase, thefinding that antidepressant drugs blocking the re-uptake of serotonin are more effective than othertypesof antidepressants in patients with OCD, irrespective of levelsof depression at the outset, should not be misinterpreted as suggesting that they are more effective in OCD than they are in depression. Indeed, for depression response to treatment is often complete, whereas the response of OCD to treatment is more likely to be graded and incomplete, although reduction in clinical symptoms and improvement in quality of life appear worthwhile (Goodman et a!, 1992) .
Stability of combined results
The magnitude of mean effect sizes should be interpreted in the light of another descriptive statistic, thevariation aroundthemean. For some of the dependent variables considered, @2 test revealed significant heterogeneity within the set of effect sizes computed from independent trials. The obvious implication is that clinical response to treatment varied markedly, since trials differed in many other respects beside the criteria used to group them together. The large amount of variation among the trials suggests that it is difficult to obtain closely comparable populations across centres merely by utilising diagnostic categories alone. Thus, trials are required in which the major components affecting clinical response (for example patient's diagnostic status, psychiatric and physical co-morbidity, patient's social environment, care setting, treatment given, and measuring operations) are explicitly described on standard measures, and the effect of treatment can be investigated in more homogeneous subcategories of patients (Marks, 1982; Fiske, 1983) .
Conclusions
The findings obtained in the present meta-analysis showed that antidepressant drugs are effective in the short-term treatment of patients suffering from OCD, the increase in improvement rate over placebo being 61.3Â°/a, 28.5Â°/o, 28.2Â°/o and 21.6Â°/a for clomipramine, fluoxetine, fluvoxamine, and sertraline, respectively; and although the increase in improvement rate over placebo was greater for clomipramine than for SSRIs, direct comparison between these drugs showed that they had similar efficacy on obsessiveâ€"compulsive symptoms. These findings suggest that large-scale controlled comparative studies of clomipramine and SSRIs are required in order to reach firm conclusions on the differential efficacy of these drugs.
Furthermore, since OCD is a long-lasting disorder and the superiority of antidepressant drugs over placebo has been reported to be most apparent during the initial weeks of treatment (Marks et a!, 1980 (Marks et a!, , 1988 Cottreaux et a!, 1990) 
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